Martingale Asset Management’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.02M Sell
35,442
-2,103
-6% -$123K 0.05% 377
2026
Q2
$2.18M Buy
37,545
+13,553
+56% +$736K 0.05% 371
2026
Q1
$1.39M Hold
23,992
– – 0.04% 421
2025
Q4
$1.11M Buy
23,992
+401
+2% +$17.9K 0.03% 453
2025
Q3
$850K Buy
23,591
+11,452
+94% +$379K 0.02% 519
2025
Q2
$395K Buy
+12,139
New +$398K 0.01% 657
2024
Q4
– Sell
-15,605
Closed -$1.78M – 832
2024
Q3
$1.78M Sell
15,605
-1,664
-10% -$150K 0.04% 342
2024
Q2
$1.3M Buy
17,269
+1,429
+9% +$97.3K 0.03% 393
2024
Q1
$1.08M Sell
15,840
-3
-0% -$208 0.02% 452
2023
Q4
$995K Buy
+15,843
New +$823K 0.02% 449
2022
Q4
– Sell
-33,513
Closed -$806K – 870
2022
Q3
$806K Buy
+33,513
New +$850K 0.02% 497

Other funds holding PCVX

Martingale Asset Management's PCVX Position: Q3 2026 in Review

Martingale Asset Management reduced its Vaxcyte (PCVX) stake by 5.6% in Q3 2026, selling an estimated $123K and leaving 35,442 shares worth $2.02M. The position accounts for 0.05% of the portfolio, ranked #377.

Martingale Asset Management first reported a position in PCVX in Q3 2022 and has held it in 11 quarters since. The position peaked at $2.18M in Q2 2026. 356 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • Martingale Asset Management held 35,442 shares of Vaxcyte worth $2.02M as of Q3 2026.
  • Martingale Asset Management sold 2,103 Vaxcyte shares in Q3 2026, an estimated $123K.
  • Vaxcyte made up 0.05% of Martingale Asset Management's portfolio in Q3 2026, its #377 holding.
  • Martingale Asset Management first reported a position in Vaxcyte in Q3 2022 and has held it in 11 quarters since.
  • Martingale Asset Management's Vaxcyte position peaked at $2.18M in Q2 2026.
  • 356 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Martingale Asset Management's 13F filing for Q3 2026, filed 12 Nov 2026.